Kat J. McAlpine
Kat J. McAlpine is a freelance science writer and science communications consultant based in Boston.
Eligible patients in BMC’s Center of Excellence in Sickle Cell Disease may soon be relieved of debilitating pain through transformative gene therapies
Pharmaceutical manufacturers are working to expand access to CAR T clinical trials by partnering with hospitals like BMC that care for racially diverse patients.
CAR T, a personalized cell therapy, has been a game-changer for certain blood cancers, but its high cost has been a huge barrier to equitable access.